

October 31, 2024



ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2024

President and CEO Joe Burnett Interview Highlighted on Bloomberg Intelligence Vanguard's of Healthcare Podcast Today

SOLANA BEACH, CA / ACCESSWIRE / October 31, 2024 /ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced participation in multiple investor conferences and interview formats including Bloomberg Intelligence Vanguard's of Healthcare Podcast series published today. The link to the interview published this morning on Bloomberg can be found [HERE](#).

Healthcare Conferences with Participation of ClearPoint Neuro Management Include:

- [UBS Global Healthcare Conference in Rancho Palos Verdes, CA on November 13, 2024](#)
- [Stifel Healthcare Conference in New York City, NY on November 18 and 19, 2024](#)
- [Canaccord Genuity 18th Annual MedTech, Diagnostics and Digital Health and Services Forum in New York City, NY on November 21, 2024](#)
- [Piper Sandler 36th Annual Healthcare Conference in New York City, NY on December 4, 2024](#)
- [Stifel MedTech Madness West Coast Bus Tour in Laguna Beach, CA on December 9, 2024](#)

Members of the ClearPoint Neuro management team will be onsite and available for in-person investor meetings with those who are registered to attend the various conferences.

About ClearPoint Neuro

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery.

The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the context of the federal securities laws, which may include the Company's expectations for the future performance, revenues, and operating expenses, and the adequacy of cash and cash equivalent balances to support operations and meet future obligations. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's ability to maintain its current relationships with biologics and drug delivery partners or enter into new relationships with such partners; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2024, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, which the Company intends to file with the Securities and Exchange Commission on or before November 14, 2024. The Company does not assume any obligation to update these forward-looking statements.

Contact:

Media Contact:

Jacqueline Keller, Vice President of Marketing

(888) 287-9109 ext. 4

info@clearpointneuro.com

Investor Relations:

Danilo D'Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com

SOURCE: ClearPoint Neuro

View the original [press release](#) on accesswire.com